SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Tiwari RC, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2004; 54: 829.
  • 2
    Ardalan B, Luis R, Jaime M, et al. Biomodulation of fluorouracil in colorectal cancer. Cancer Invest. 1998; 16: 237251.
  • 3
    Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998; 16: 301308.
  • 4
    Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol. 1991; 9: 19671972.
  • 5
    Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000; 6: 13221327.
  • 6
    Lenz HJ. The use and development of germline polymorphisms in clinical oncology. J Clin Oncol. 2004; 22: 25192521.
  • 7
    Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer. 2004; 91: 344354.
  • 8
    Goldberg RM. Current approaches to first-line treatment of advanced colorectal cancer. Clin Colorectal Cancer. 2004; 4(Suppl 1): S9S15.
  • 9
    Hoff PM, Pazdur R. Progress in the development of novel treatments for colorectal cancer. Oncology (Huntingt). 2004; 18: 705708.
  • 10
    Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343: 905914.
  • 11
    Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22: 229237.
  • 12
    Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988; 48: 17221726.
  • 13
    Zeghari-Squalli N, Raymond E, Cvitkovic E, et al. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res. 1999; 5: 11891196.
  • 14
    Hoff PM, Saad ED, Pazdur R, et al. Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. Invest New Drugs. 2004; 22: 307313.
  • 15
    Wasserman E, Cuvier C, Lokiec F, et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol. 1999; 17: 17511759.
  • 16
    Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22: 2330.
  • 17
    Kemeny N, Tong W, Gonen M, et al. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol. 2002; 13: 14901496.
  • 18
    Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 1997; 15: 32233229.
  • 19
    Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995; 55: 14071412.
  • 20
    Morrison GB, Bastian A, Dela Rosa T, et al. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum. 1997; 24: 8388.